Objective: The aim of this study is to evaluate the influence of antenatal magnesium sulfate (MgSO 4 ) treatment on the clinical responsiveness of the ductus arteriosus to indomethacin prophylaxis and on that of symptomatic patent ductus arteriosus (sPDA) to indomethacin treatment in premature neonates.
Introduction
Magnesium sulfate (MgSO 4 ) is the most commonly used first-line tocolytic in North America, 1, 2 and is also frequently used to treat preeclampsia. 3 Although the safety and efficacy of MgSO 4 in termgestation preeclampsia have been well established, 4 tocolytic MgSO 4 administered to stall preterm labor has been suggested to be associated with adverse neonatal effects, 5 and its use therefore remains controversial. 6, 7 After birth, patent ductus arteriosus (PDA) increases pulmonary blood flow and induces redistribution of systemic blood flow. This redistribution subsequently results in neonatal complications such as congestive heart failure, pulmonary edema or hemorrhage, intraventricular hemorrhage and necrotizing enterocolitis in premature neonates. A symptomatic PDA (sPDA) is estimated to occur in 55 to 70% of extremely preterm neonates (<28 weeks' gestation) and requires either pharmacological or surgical treatment to prevent development of complications. 8 Indomethacin, a prostaglandin inhibitor, is effective in closing a PDA, and is used as either symptomatic or prophylactic therapy. Randomized controlled trials have shown that prophylactic treatment with indomethacin contributes to a reduction in the incidence of an sPDA, the need for duct ligation and severe intraventricular hemorrhage in preterm infants. 9, 10 In recent years, a significantly increased incidence of an sPDA has been noted among extremely low birth weight infants with antenatal exposure to MgSO 4 .
11 However, limited information is available with regard to the incidence of sPDA with or without antenatal exposure to MgSO 4 with respect to infants receiving indomethacin prophylaxis, and whether or not antenatal exposure to MgSO 4 influences the clinical response to indomethacin prophylaxis and indomethacin treatment remains to be investigated. This study aimed to evaluate the influence of antenatal MgSO 4 treatment on the clinical responsiveness of the ductus arteriosus to indomethacin prophylaxis and on that of sPDA to indomethacin treatment in extremely preterm neonates.
Methods
This study was conducted at our hospital, Takatsuki General Hospital (Osaka, Japan), which has a level 3, 51-bed neonatal intensive care unit that admits 500 patients annually. We retrospectively reviewed the medical records of all extremely preterm neonates (infant with a gestational age (GA) of <28 weeks) born at our hospital between October 2004 and December 2008. GA was determined by first trimester ultrasound or by obstetrical dating of the pregnancy and examination of the infant after birth. Infants with chromosomal abnormalities were excluded. Permission to collect data for this project was granted by the hospital ethics committee. Because of the study's retrospective design, parental consent was waived.
At our hospital, MgSO 4 is provided to pregnant women in danger of delivering prematurely (<32 weeks' gestation) in cases in which ritodrine administration is insufficient to prevent labor. Our standard protocol consists of a maintenance infusion of 0.5 to 1 g h À1 without a bolus infusion. MgSO 4 is also administered to preeclamptic mothers to prevent eclamptic seizures.
In this study, total administered dose of MgSO 4 was assessed by reviewing nursing charts. Infants whose mothers had been provided MgSO 4 before birth constituted the 'antenatal MgSO 4 ' group, with all other infants constituting the 'nonantenatal MgSO 4 (control)' group. Perinatal factors such as GA at delivery, birth weight, gender, mode of delivery, administration of surfactant, administration of antenatal steroids, administration of ritodrine tocolysis, premature rupture of membranes and PDA outcome were compared between groups.
All extremely preterm neonates born at our hospital received prophylactic indomethacin within 6 h of birth at a three-dose course of 0.1 mg kg À1 administered intravenously over 6 h, at 24-h intervals.
The primary outcome of this study was early ductus arteriosus closure following prophylactic indomethacin administration. All infants had undergone at least one echocardiographic examination within 5 days of birth and were considered to have had 'early closure' if no color Doppler flow was present in the region of the ductus without indomethacin treatment.
The secondary outcome was sPDA and its successful response to indomethacin treatment. A diagnosis of an sPDA was made based on clinical signs, including heart murmur, bounding pulses, hyperdynamic precordium, respiratory distress, tachycardia, increased oxygen requirements and decreased urine output. Indomethacin was administered to treat an echocardiographically confirmed sPDA at three doses of 0.2 mg kg À1 at 24-h intervals.
Statistical analysis
Comparisons between MgSO 4 and control groups of extremely preterm neonates were conducted using either the w 2 -test or the Fisher's exact test, for variables with an expected value of <5. Continuous variables with skewed distributions were analyzed using the Mann-Whitney U-test. The effect of exposure to MgSO 4 on PDA outcome, after controlling for possible confounding variables, was assessed using univariate and multivariate logistic regression analysis. All analyses were conducted using SPSS 17.0 (SPSS Japan, Tokyo, Japan).
Results
A total of 160 neonates were enrolled in this study, including 41 neonates exposed to MgSO 4 and 119 not exposed. Indications for MgSO 4 administration were tocolysis in 40 cases and preeclampsia in 1. Mothers who did not receive MgSO 4 delivered not because of preterm labor but because of obstetric complications such as oligohydramnios, clinical chorioamnionitis, placenta previa with hemorrhage or nonreassuring fetal heart rate pattern. No significant between-group differences were noted with regard to GA, birth weight, gender, mode of delivery or administration of surfactant ( Table 1 ). The MgSO 4 -exposed infants received antenatal steroids more frequently than the control infants (90 vs 68%, respectively), and also received ritodrine for tocolysis more frequently (98 vs 79%, respectively). Premature rupture of membranes was observed less frequently among infants exposed to MgSO 4 .
Incidence of early closure of the ductus arteriosus was significantly lower among infants exposed to MgSO 4 than control infants (59 vs 84%, respectively; P ¼ 0.002; Table 2 ). Further, sPDA occurred more often among MgSO 4 -exposed infants than among those not exposed (46% (19 of 41) vs 24% (28 of 119), respectively; P ¼ 0.006). Successful response to indomethacin treatment was observed in 68% (13 of 19) of antenatally exposed infants and in 50% (14 of 28) of controls. However, no significant between-group difference was noted for the need for surgical treatment of a PDA (32% (6 of 19) vs 50% (14 of 28)).
Infants exposed to antenatal MgSO 4 were further separated into two subgroups according to the total dose of MgSO 4 received to form low-dose (<50 g, n ¼ 19) and high-dose groups (X50 g, n ¼ 22). No significant differences in incidence of early closure of Multivariate logistic regression analysis showed that antenatal MgSO 4 treatment was an independent predictor of failure of early ductus arteriosus closure following indomethacin prophylaxis after adjusting for potential confounding variables, including antenatal steroids, ritodrine tocolysis and premature rupture of membranes (adjusted odds ratio (OR), 4.03; 95% confidence interval, 1.65 to 9.80; P ¼ 0.002; Table 3 ). Further, antenatal exposure to MgSO 4 was also associated with occurrence of an sPDA in univariate analysis (unadjusted OR, 2.81; 95% confidence interval, 1.33 to 5.92; P ¼ 0.007). Although the OR decreased from 2.81 to 2.26, this association remained significant (P ¼ 0.047) after controlling for the confounding variables. The association between antenatal steroids and occurrence of an sPDA observed in the univariate analysis (unadjusted OR, 2.56; 95% confidence interval, 1.05 to 6.29; P ¼ 0.04) disappeared after adjusting for the confounding variables (adjusted OR, 2.03; 95% confidence interval, 0.80 to 5.17; P ¼ 0.137).
Discussion
Our retrospective study of 160 consecutively admitted neonates born at <28 weeks' gestation showed that antenatal exposure to MgSO 4 in these neonates reduces the constrictive response of the ductus arteriosus to indomethacin prophylaxis. Further, antenatal exposure to MgSO 4 was also shown to be associated with an increased risk of developing an sPDA. However, antenatal use of MgSO 4 was not found to influence the response of an sPDA to indomethacin treatment.
The ductus arteriosus is a muscular-type artery with tunica media dominated by smooth muscle cells. Functional closure of the ductus lumen after birth is primarily due to smooth muscle constriction, 12 with an increase in intracellular calcium concentration contributing to constriction of the ductus arteriosus. 13 Magnesium acts as a calcium antagonist, blocking calcium ion entry into the smooth muscles.
14, 15 Satake et al. The relationship between antenatal MgSO 4 and transient neonatal hypermagnesemia after birth have been shown in several clinical studies. One study conducted among preterm (p33 weeks' gestation) infants found that antenatal MgSO 4 administration resulted in hypermagnesemia during the first 3 to 7 days of life. 18 In MgSO 4 -exposed infants, the serum magnesium concentration remained elevated for the first 72 h of life, and concentration was even higher in preterm infants. 19 These previous findings may explain the observation in this study of differing responses of the ductus arteriosus to indomethacin between prophylactic administration at early postnatal age and treatment at advanced postnatal age. Our study may be the first to provide information with regard to the negative effects of antenatal MgSO 4 on the constrictive response of the ductus arteriosus during indomethacin prophylaxis treatment in extremely preterm neonates.
Several clinical studies have suggested a relationship between magnesium and PDA in premature neonates. One prospective study demonstrated a significant relationship between infants with a delayed closure of the ductus arteriosus born before 32 gestational weeks of age and elevated serum magnesium concentration at birth. 20 Further, a cohort study showed increased incidence of an sPDA among infants with antenatal MgSO 4 exposure compared with unexposed infants (67 vs 60%, respectively; P<0.018).
11
Substantial discrepancy exists with regard to the incidence of an sPDA among MgSO 4 -exposed and control infants between the results noted by del Moral et al. 11 (67 vs 60%, respectively) and our own results (46 vs 24%, respectively). Indomethacin prophylaxis may have contributed the low incidence of an sPDA in our study. A randomized study conducted among infants aged between 26 and 34 gestational weeks found no significant difference in incidence of an sPDA between infants exposed (2 of 15) and not exposed to 21 may be due to the small sample size with a relatively high range of GA seen in the previous study.
del Moral et al. 11 reported an increased risk of an sPDA with relatively high doses (X50 g) of antenatal MgSO 4 in infants aged X26 gestational weeks. These authors speculated that the effect of MgSO 4 exposure on risk of an sPDA development in more mature infants was related to the total amount of MgSO 4 provided to the mother. This speculation may be supported by findings from an animal study citing a developmental increase in the dilator effect of MgSO 4 in rabbit pulmonary artery tissue. 22 However, no increased risk of failure in early closure of the ductus arteriosus or sPDA was observed with elevated doses of antenatal MgSO 4 in this study, which is possibly due to the relatively low GA of our population.
A potential limitation of this study is its retrospective design, which introduces selection bias for the MgSO 4 treatment and may relate the differences of demographic characteristics between the two study groups. Although we adjusted for the identified differences by using multivariate logistic regression models, certain confounding variables may have slipped into our analysis. The second limitation of this study was that almost all mothers of MgSO 4 -exposed infants were administered with ritodrine, and this ritodrine exposure may have synergistically affected the response of the ductus arteriosus to the MgSO 4 treatment . Third, a type II error may have occurred due to the relatively small sample size in our study. Although we found no significant difference in need for surgical treatment of an sPDA between the two study groups, adequate power of this study would require a total sample size of 304 infants (b ¼ 0.20, a ¼ 0.05).
In conclusion, we demonstrated that the response to indomethacin prophylaxis of the ductus arteriosus is markedly decreased among extremely preterm neonates antenatally exposed to MgSO 4 , whereas risk of an sPDA is increased. Given these findings, neonatal physicians should take into account maternal information with regard to MgSO 4 administration with respect to ductus arteriosus management using indomethacin prophylaxis. Although our results do not directly affect the decision-making of obstetric physicians with regard to MgSO 4 treatment, the findings of increased failure of early ductus arteriosus closure and increased incidence of an sPDA provide noteworthy information, which may aid in designing future prospective clinical trials.
